Intriguingly, the two IFN mice eventually surviving the tumor challenge showed early reactivity against both OVA and tTA, suggesting that immune response to multiple surrogate TSAs might be required to achieve durable protection. The gene discussed is IFNA1; the disease is neoplasm.